share_log

Transcode Therapeutics | 10-Q: Q1 2024 Earnings Report

Transcode Therapeutics | 10-Q: Q1 2024 Earnings Report

Transcode Therapeutics | 10-Q:2024財年一季報
美股SEC公告 ·  05/16 10:23

牛牛AI助理已提取核心訊息

Transcode Therapeutics, a platform delivery company focusing on oncology, reported no income tax benefit or expense for Q1 2024, maintaining a full valuation allowance against its net deferred tax assets due to historical net operating losses. The company is appealing a Nasdaq delisting notice for failing to meet the Minimum Bid Price Requirement, with a hearing scheduled for June 25, 2024. Transcode's lead therapeutic candidate, TTX-MC138, targets miRNA-10b, a master regulator in various cancers. The company received FDA approval to conduct a Phase I/II clinical trial for TTX-MC138, expected to commence mid-2024. Other preclinical stage programs include TTX-siPDL1, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, all utilizing the proprietary TTX delivery mechanism. Transcode's restructuring in December 2023 reduced headcount and prioritized the...Show More
Transcode Therapeutics, a platform delivery company focusing on oncology, reported no income tax benefit or expense for Q1 2024, maintaining a full valuation allowance against its net deferred tax assets due to historical net operating losses. The company is appealing a Nasdaq delisting notice for failing to meet the Minimum Bid Price Requirement, with a hearing scheduled for June 25, 2024. Transcode's lead therapeutic candidate, TTX-MC138, targets miRNA-10b, a master regulator in various cancers. The company received FDA approval to conduct a Phase I/II clinical trial for TTX-MC138, expected to commence mid-2024. Other preclinical stage programs include TTX-siPDL1, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, all utilizing the proprietary TTX delivery mechanism. Transcode's restructuring in December 2023 reduced headcount and prioritized the Phase I clinical trial of TTX-MC138. The company entered a collaboration with Debiopharm to develop targeted mRNA delivery to cancer cells. Despite regaining compliance with Nasdaq's stockholders' equity requirement, Transcode's common stock faces potential delisting due to not meeting the Minimum Bid Price Requirement. Financially, Transcode has not generated revenue from product sales and has incurred significant operating losses. As of March 31, 2024, the company had an accumulated deficit of approximately $49.7 million and cash of $4.9 million, expected to fund operations into Q3 2024. Transcode's future plans include advancing clinical development of TTX-MC138, expanding its product candidate pipeline, and seeking additional funding to support operations.
平台型腫瘤遞送公司Transcode Therapeutics報告稱,2024年第一季度未獲得所得稅減免或開支,由於歷史淨營業虧損,繼續針對淨遞延稅資產保持完全減值準備。該公司正在上訴納斯達克因未達到最低買入價要求而發出的退市通知,聽證會定於2024年6月25日舉行。Transcode的領先治療候選藥物TTX-MC138針對多種癌症中的主導調節因子miRNA-100億元。該公司獲得了FDA批准,開展TTX-MC138的1/2期臨床試驗,預計將於2024年中期開始。其他臨床前階段項目包括使用專有TTX遞送機制的TTX-siPDL1、TTX-RIGA、TTX-CRISPR和TTX-mRNA。Tra...展開全部
平台型腫瘤遞送公司Transcode Therapeutics報告稱,2024年第一季度未獲得所得稅減免或開支,由於歷史淨營業虧損,繼續針對淨遞延稅資產保持完全減值準備。該公司正在上訴納斯達克因未達到最低買入價要求而發出的退市通知,聽證會定於2024年6月25日舉行。Transcode的領先治療候選藥物TTX-MC138針對多種癌症中的主導調節因子miRNA-100億元。該公司獲得了FDA批准,開展TTX-MC138的1/2期臨床試驗,預計將於2024年中期開始。其他臨床前階段項目包括使用專有TTX遞送機制的TTX-siPDL1、TTX-RIGA、TTX-CRISPR和TTX-mRNA。Transcode於2023年12月進行了重組,減少了人員規模,將TTX-MC138的1期臨床試驗作爲優先任務。該公司與德必昂合作開發針對癌細胞的靶向mRNA遞送。儘管重新符合納斯達克股東權益要求,但由於未達到最低買入價要求,Transcode的普通股仍面臨潛在的退市風險。在財務上,Transcode尚未從產品銷售中產生收入,併產生了重大營業虧損。截至2024年3月31日,該公司的累計赤字約爲$49.7百萬,現金爲$4.9百萬,預計將資助運營至2024年第3季度。Transcode的未來計劃包括推進TTX-MC138的臨床開發,擴大其產品候選藥物管線,並尋求額外的資金支持運營。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。